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A Guide to Approaching Regulatory Considerations
for Lentiviral-Mediated Gene Therapies
Michael White,1,2 Roger Whittaker,1–3 Carolina Ga´ndara,1,2 and Elizabeth A. Stoll1,2,*
1Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, United Kingdom; 2Controlling Abnormal Network Dynamics using Optogenetics (CANDO)
Consortium; Newcastle University, Newcastle upon Tyne, United Kingdom; and 3Department of Clinical Neurophysiology, Royal Victoria Infirmary, Queen Victoria
Road, Newcastle upon Tyne, United Kingdom.
Lentiviral vectors are increasingly the gene transfer tool of choice for gene or cell therapies, with multiple
clinical investigations showing promise for this viral vector in terms of both safety and efficacy. The third-
generation vector system is well characterized, effectively delivers genetic material and maintains long-term
stable expression in target cells, delivers larger amounts of genetic material than other methods, is non-
pathogenic, and does not cause an inflammatory response in the recipient. This report aims to help academic
scientists and regulatory managers negotiate the governance framework to achieve successful translation of
a lentiviral vector-based gene therapy. The focus is on European regulations and how they are administered
in the United Kingdom, although many of the principles will be similar for other regions, including the
United States. The report justifies the rationale for using third-generation lentiviral vectors to achieve gene
delivery for in vivo and ex vivo applications; briefly summarizes the extant regulatory guidance for gene
therapies, categorized as advanced therapeutic medicinal products (ATMPs); provides guidance on specific
regulatory issues regarding gene therapies; presents an overview of the key stakeholders to be approached
when pursuing clinical trials authorization for an ATMP; and includes a brief catalogue of the documen-
tation required to submit an application for regulatory approval of a new gene therapy.
Keywords: translational studies, gene therapy, GMP manufacture, GLP testing, lentivirus, AAV
INTRODUCTION
THE ESTABLISHMENT OF GENE THERAPY as a clinical
technique has provided a revolutionary approach
to a wide range of previously untreatable diseases.
As with any novel therapy, the promised benefits
to the patient must be balanced against the po-
tential for harm. The use of retroviral vectors, and
specifically lentivirus-based platforms, remains in
its infancy, and public perception, ethical consid-
erations, and a stringent regulatory framework
all present potential barriers to translation of
preclinical advances to the bedside. Nevertheless,
with a structured approach and close engage-
ment with the relevant stakeholders, this can be
achieved, as is set out below.
Third-generation lentiviral vectors represent
some of the safest and easiest-to-use vectors avail-
able for the delivery of genes into mammalian tissue.
The advantages of these engineered viral vector–
based gene therapies are that they effectively deliver
genetic material and maintain long-term stable ex-
pression in target cells, deliver larger amounts of
genetic material than other methods, are nonpatho-
genic, and do not cause an inflammatory response in
the recipient. For these reasons, this system is in-
creasingly the vector of choice for in vivo and ex vivo
delivery of genes to be used in gene and cell thera-
pies, respectively. Already, several clinical inves-
tigations have shown great promise for lentiviral
vectors in terms of both safety and efficacy.
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This report aims to present justification for the
use of lentiviral vectors in clinical applications of
gene therapy. First, third-generation lentiviral
vectors are described and a rationale is provided for
using this vector system to achieve gene transfer
for in vivo and ex vivo applications. Second, the
regulatory considerations that cover each of these
components of the gene therapy are introduced.
Third, an overview of the extant regulatory re-
quirements and standards for clinical use of this
advanced therapeutic medicinal product (ATMP)
are provided. Fourth, the key stakeholders to be
approached when pursuing clinical trials authori-
zation for an ATMP are introduced. Finally, the
documentation required to achieve regulatory ap-
proval for this type of ATMP is catalogued.
RATIONALE FOR USING LENTIVIRAL
VECTOR SYSTEMS FOR TRANSLATIONAL
GENE THERAPIES
Third-generation lentiviral vectors
are optimal tools for gene therapy
Although lentiviral vectors are derived from
human immunodeficiency virus type 1 (HIV-1)
and related wild-type viruses, modified lentiviral
vectors are nonpathogenic and not capable of
replication after the initial gene delivery event.
The RNA-based vector has been engineered to
deliver genes to cells and tissues safely and effec-
tively for the purposes of gene therapy. A descrip-
tion of characteristics of lentiviral-based vectors
compared to other viral vector-based options for
achieving gene therapy is shown in Table 1. Spe-
cifically, lentiviruses can deliver up to 8.5 kB of
genetic material, which is then reverse transcribed
in the target cell and integrated into the genome to
achieve long-term stable expression. The compo-
nents of the lentivector transfer plasmid are shown
in Fig. 1.
The HIV-1-derived third-generation lentiviral
vector manufacturing system originated from the
laboratories of Didier Trono and David Baltimore.
It represents one of the safest and easiest-to-use
vectors available for the delivery of genes into
mammalian tissue.1–3 The resultant lentiviral
vectors are replication deficient, and are used in
many laboratories around the world at this time for
in vivo applications.3,4 Furthermore, they are de-
signed to be extraordinarily unlikely to become
replication competent, with more than two thirds
of the parental viral genome deleted from the final
packaged vector (including the abolition of all
virus-replication genes). These viruses have self-
inactivating properties to prevent integrated genes
from being repackaged in the event a subsequent
infection ever occurs.
Third-generation lentiviral vector systems also
provide a margin of personal and public safety,
with key improvements to previous systems: dele-
tion of a crucial viral transcription activator (tat)
gene and its regulatory region rendering self-
inactivating (SIN) vectors, and the separation of
viral packaging genes (gag, pol, and rev) onto two
plasmids. These new safety measures offer signif-
icant biosafety advantages, along with other key
features of previous lentiviral vector systems, such
as: the accessory genes vif, vpr, vpu, and nef that
are critical for in vivo replication and pathogenesis
of the virus have been deleted, and a heterologous
envelope protein (e.g., VSV-G) is used in place of
the native HIV-1 envelope protein. As a result, the
third-generation system is the safest to date be-
cause it only conserves three of the nine genes from
the parental HIV-1 (gag, pol, and rev), and it relies
on four separate plasmids for the production of
lentiviral vectors, thus virtually eliminating the
Table 1. Lentivirus as an optimal choice for achieving
gene therapy for clinical applications
Features Adenovirus AAV Lentivirus
Type of virus ds DNA ss DNA RNA
Infection efficiency >90% *30% *30%
Infection of post-mitotic cells Yes Yes Yes
Can get titers of >109 infectious units/mL Yes Yes Yes
Viral packaging capacity 7.6 kb 4.0 kb 8.5 kb
Capable of integrating into host genome No No Yes
Stable continuous expression
in post-mitotic cells
No Yesa Yes
Derived from pathogenic virus Yes No Yes
Capable of propagating pathogenic virus Yes No Nob
Inflammatory response in vivo High Low Low
Potential for oncogenic transformation Low Low Lowc
Local infection only (no retrograde
transport in neurons)
No No Yesd
aStable continuous expression of the target gene is critical for clinical
success; lentivirus has been shown to integrate stably and permanently
into the host-cell genome. While AAV can occasionally integrate in the host
genome, this vector may not express continuously in all conditions.
bBoth adenoviral and lentiviral gene delivery vectors are derived from
pathogenic viruses; clinical-grade adenovirus remains pathogenic, while
clinical-grade lentivirus is non-pathogenic and non-replication competent.
cLentivirus-based gene delivery does not induce tumors in animal
models, unless tumor suppressor pathways are specifically targeted.
Molecular analysis has shown that genes delivered by lentivirus do not
integrate into oncogenic hot spots of host genome, although random
insertional mutagenesis does occur, causing a non-zero risk of oncogenic
transformation of the target cell.
dLentivirus-based gene delivery (packaged with VSV-G pseudotyped
envelope protein) does not cause retrograde transport from axon terminals
to cell bodies elsewhere in the brain. This feature provides a localized
infection in a small area that can be removed surgically if necessary or
desired. In contrast, AAV has over a dozen different serotypes that have
different expression patterns in different species, with implications for the
interpretation of results gained from preclinical testing in model systems.
Therefore, lentivirus may be favored for neurological indications.
AAV, adeno-associated virus.
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possibility of a wild-type virus originating through
recombination events.2,3
Manufacture of the third-generation lentiviral
vectors was first described by Dull and Naldini.2
To produce third-generation lentiviral vectors,
the lentivector transfer plasmid and three plas-
mids containing packaging and envelope genes are
transfected into a HEK293T producer cell line,
which then assembles the virus and releases it
into the media. The pseudoviral particles are then
concentrated to high titer and tested for sterility,
stability, toxicity, and other key characteristics
prior to use in ex vivo or in vivo clinical applica-
tions. A schematic of the entire process is shown
in Fig. 2.
The third-generation lentivirus systems to be
used are such that they have been extensively
modified and are regarded as being stable, as are
the inserted sequences. The lentiviral vector sys-
tem to be used within this protocol is considered to
be ‘‘Third Generation’’ as defined by the UKHealth
and Safety Executive SACGM Compendium of
Guidance 2.11.9; similar guidance is provided by
the U.S. Food and Drug Administration (FDA)
within the Cellular and Gene Therapy Guidance
Documents.5,6 The risk of dissemination of the
described vector is extremely low, as this engi-
neered vector is replication incompetent and self-
inactivating. The extensive modification of the viral
vector also prevents homologous recombination
with other related viruses. The intended use of a
lentiviral-mediated gene therapy product for clin-
ical investigation falls under ‘‘contained use’’ as
defined by the SACGM Compendium of Guidance
6.1.17.7
Key clinical trials conducted with lentiviral-
mediated gene therapies
The use of lentiviruses for gene therapy include
HIV-based vectors8,9 and non-HIV-based vec-
tors.10,11 Recent clinical investigations have pro-
vided important precedents for using lentivirus as
a vector system for translational gene therapies.
According to The Journal of Gene Medicine, there
are currently 144 lentiviral vector-based clinical
trials (138 with an open status).12 This activity
demonstrates a substantial increase over the past 3
years. In October 2014, there were 89 lentiviral
vector-based clinical trials (86 with an open sta-
tus). Over the past several years, clinical trials in
Europe and the United States have demonstrated
safety and initial indications of efficacy for various
lentivirus-mediated gene therapies.
Many of the gene therapies using lentivirus
that have been trialed to date have been viral-
mediated engineered-cell therapies (ex vivo gene
therapies).13 Other ongoing trials exist for pri-
mary immune deficiency diseases such as severe
combined immunodeficiency and Wiskott–Aldrich
syndrome.14–16
Figure 1. Schematic representation of a third-generation lentivector transfer plasmid. This is a circular, double-stranded DNA containing the genetic
elements necessary for the production of lentiviral vectors and the genes that will be delivered into the target cells. Justification for each element of the
lentivector transfer plasmid and packaging plasmids must be provided to the regulatory body, and confirmation of the sequences for these plasmids must be
provided. For example, while a fluorescent reporter gene or selection marker may be required for ease of preclinical experimentation, these features may need
to be removed from the construct prior to clinical-grade production. LTRs, long terminal repeats.
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The Pro-Savin Study involved direct injection
of a lentiviral vector directly into the human pa-
tient, specifically into the central nervous sys-
tem for the treatment of Parkinson’s disease.
Recently-published results from this clinical trial
support the safety profile of the lentiviral gene
delivery method and initial indications of slowed
disease progression.17 This trial utilized an EIAV
vector genome that expressed the tricistronic cas-
sette called pONY8.1TSIN, a self-inactivating vec-
tor containing three genes—human aromatic
l-amino acid decarboxylase (AADC, E.C. 4.1.1.28),
the catalytic domain of human tyrosine hydroxy-
lase (TH, E.C. 1.14.16.2), and human GTP cyclo-
hydrolase (GTPCH, E.C. 3.5.4.16)—which together
allow the biosynthesis of dopamine in targeted
neurons.18,19 Preclinical efficacy data in rats had
demonstrated the efficacy of gene delivery and ob-
servations of functional improvement prior to the
clinical trial.20
New gene-editing tools such as CRISPR open the
door to manipulating pathological processes in
other disease indications using either ex vivo
cell therapies or direct in vivo application. Initial
studies in animal models suggest that viral-
mediated gene delivery may be able to restore
function in primary immune deficiency diseases
such as X-linked chronic granulomatous disease
and X-linked hyper-IgM syndrome.21–23
EXTANT REGULATORY REQUIREMENTS
AND STANDARDS FOR CLINICAL USE
FOR ATMPS
The regulatory requirements across countries
and continents will vary, but the aims are simi-
lar: to ensure the safety and well-being of citi-
zens. Within the European Union (EU), there are a
number of Directives and Regulations in place de-
tailing the requirements that need to be followed
in order to obtain national authorizations for clin-
ical trials. Regulations are legal acts of the EU
that become immediately enforceable as law in all
member states. ADirective requiresmember states
to achieve particular results but without dictating
the means of achieving that result. A list of the
main directives and regulations related to clinical
trials of ATMPs is included within Table 2.
The EU also releases guidelines providing ad-
vice on the best or most appropriate way to fulfil
legal obligations. The EU has released guidelines
supporting a risk-based approach to cover quality,
safety, efficacy, manufacturing, and biological as-
pects.24 The risk-based approach is a strategy to
Figure 2. Schematic for manufacturing processes to produce and test clinical-grade gene therapies.
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determine the level of data required and to support
justification for any deviations made from Direc-
tives. The FDA has released similar guidance doc-
uments to support development of gene therapies
and other ATMPs. More information on consid-
erations for Good Manufacturing Practice (GMP)
manufacture, and validation of lentivirus-based
gene therapies for preclinical and translational
research teams is available in concurrent papers.
A major key to success when developing an
ATMP is to ensure that there is early engagement
with the relevant regulatory bodies. This ensures
that regulatory bodies are given plenty of warn-
ing of complex projects and are able to provide
comments, reducing the potential for lengthy and
costly delays. Within the EU, this is the European
Medicines Agency (EMA). Each of the member
states has a regulatory body that provides a point of
contact for research teams within that country. In
the current EU regulatory setup, the national reg-
ulatory authority is responsible for providing ap-
provalswithin its own country for clinical trials. The
EMA is responsible for marketing approval within
the EU once the requisite body of evidence has been
compiled. With the implementation of Brexit, it is
possible that once the United Kingdom leaves the
EU, separatemarketing licenseswill be required for
the EU and the United Kingdom, in the same way
that a separatemarketing license is required for the
United States. Within the EU, the EMA provides
clarification on any product classifications.
REGULATORY CONSIDERATIONS
FOR GENE THERAPIES
For vectors derived from pathogenic viruses, the
regulatory requirements are built toward safety,
with an underlying requirement to gain as great
an understanding of the proposed gene therapy
medicinal product (GTMP) as possible. Due to the
extensive characterization studies reported with
third-generation lentivirus over the past two de-
cades, knowledge of the characteristics and safety
profile of this vector is extensive. Previously re-
ported tests may partly address the safety issues for
a selected vector system, but specific tests may be
needed to evaluate the properties and biological ef-
fects of the promoter sequence, transgene, and gene
product delivered for the novel clinical application.
The requirements for demonstration of product
characterization, biologic activity, and safety of
lentiviral vectors for gene therapy will be no dif-
ferent than for other medicinal products. However,
the approach for demonstrating safety will be un-
ique for virus-mediated gene therapies based on
the relevant biology of the product. Here, the re-
quirements for addressing the safety of a GTMP
and an outline of the justification for lentiviruses as
safe vector systems for gene delivery in clinical
applications are presented.
General goals for preclinical safety testing are:
1. To demonstrate pharmacological ‘‘proof of
concept’’ in preclinical model(s);
2. To demonstrate the dose–response relation-
ship to establish efficacy;
3. To identify an initial safe dose and subse-
quent dose-escalation schemes in human
patients based on an understanding of dose–
response relationships and pharmacology,
and how schedule of delivery affects the ac-
tivity or toxicity of the Investigational Med-
icinal Product (IMP);
4. To define the distribution of the drug through-
out the body;
5. To determine potential target organs for
toxicity and specifically the risk of toxicity in
reproductive organs;
6. To assess whether the route and/or device used
for delivery contribute to toxicity of the IMP;
7. To determine the stability of the IMP;
8. To determine whether there is a risk of
immune reaction;
9. To identify parameters for clinical monitor-
ing based on standard-of-care and risks of
the novel therapy; and
Table 2. EU Directives and Regulations related
to clinical trials involving GTMPs
Directives
98/81/EC Details the contained use of genetically modified microorganisms.
2001/20/EC Approximation of the laws, regulations, and administrative
provisions relating to the implementation of good clinical
practice in the conduct of clinical trials on medicinal products
for human use.
2001/83/ECa Community code relating to medicinal products for human use.
2003/94/EC Principles and guidelines of GMP in respect of medicinal products
for human use and IMPs for human use.
2005/28/EC Principles and detailed guidelines for good clinical practice as
regards IMPs for human use, as well as the requirements for
authorization of the manufacturing or importation of such
products.
2009/41/EC Contained use of genetically modified microorganisms.
Regulations
536/2014 Clinical trials on medicinal products for human use
1394/2007 on ATMPs.
668/2009 Implementing 1394/2007, evaluation and certification of quality
and non-clinical data relating to ATMPs.
aIncluding a number of subsequent amendments to this Directive.
GTMP, gene therapy medicinal product; GMP, good manufacturing
practice; IMP, investigational medicinal product; ATMP, advanced therapy
medicinal product.
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10. To aid in defining ‘‘at risk’’ patient popula-
tions for inclusion/exclusion criteria.
Additional goals unique to preclinical safety
testing for gene therapies are:
11. To determine the level and persistence of
gene expression, including that in target
and non-target cells;
12. To determine whether there is aberrant lo-
calization or trafficking;
13. To determine whether there is a risk of in-
sertional mutagenesis;
14. To determine whether there is germline
transfer of viral/therapeutic gene;
15. To determine the risk of viral shedding;
16. To determine the risk of generating
replication-competent virus;
17. To ascertain the sterility of the ATMP
preparation; and
18. To ascertain the sequence and structural
integrity of the genetic material.
Each of these issues is addressed in turn, with a
focus on addressing concerns of the vector itself.
Any potential for the promoter sequence, trans-
gene, or product of the transgene to influence these
factors must be justified for each gene therapy. The
use of preclinical data on related material must be
clearly specified and justified.
Data obtained from similar products may be
supportive to warrant first clinical use but are not
sufficient on their own. The variation between
promoter sequences, transgenes, disease indica-
tion, target tissue or cell type, patient character-
istics, or any other substantial novelty will support
the need for justification of a new GTMP. The
flexibility of third-generation lentivectors provides
a common core platform technology, which even-
tually may serve as precedents for novel therapies
using this vector system. However, because this is
still a new type of therapy, it should be assumed
that the vector itself must be justified.
Ultimately, the preclinical data should provide
sufficient information to allow a proper risk assess-
ment for theuse of theGTMP inhuman subjects. The
clinical safety aspects surrounding viral vectors pri-
marily relate to viral-mediated gene expression pat-
terns, risks due to integration of genetic material,
germline transfer, viral shedding, viral replication,
and virulence. Key specifications do relate to the
characteristics of the original pathogenic virus.
Here, the aim is to help to establish third-
generation lentivirus as a viral vector of choice for
clinical applications in gene therapy by providing
initial justification that such vectors can meet the
standard principles for preclinical safety testing
and providing a route for translational teams to
collect information in order to risk assess a new
GTMP.25
1. ‘‘Proof of concept’’ of pharmacodynamics
in nonclinical models
Proof-of-concept studies should generate evi-
dence to support the potential clinical effect or re-
lated biological effect of a GTMP. Studies must be
able to demonstrate that the vector is carrying out
its intended role by infecting cells within the target
organ, integrating genetic material into the host
cell DNA, and expressing mRNA and protein at
appropriate levels. Importantly, it must further be
demonstrated that the transgene is functional,
with the intended effect on cellular behavior. A
mechanism of action for the therapeutic substance
must be established to demonstrate proof of con-
cept prior to clinical investigation. This battery of
testing must be conducted in appropriate in vitro
and in vivo model systems using the most appro-
priate species and experimental paradigm for these
efficacy studies.26
2. Dose–response relationship
The effectiveness of a GTMP is influenced by
both the number of vector particles and the ex-
pression and/or integration of the delivered genes.
Therefore, dose determination should include an
estimate of the amount of gene delivered to target
cells related to a given dose of GTMP.27 In other
words, the dose should be determined not on total
viral particles alone but on the proportion of in-
fectious units capable of transducing cells (ifu) in
relation to the quantification of total viral particles
(vpu). Quantitative polymerase chain reaction
(qPCR)-based assays for quantifying nucleic acids
are appropriate to establish viral titer (in order
to measure both ifu and vpu concentrations), al-
though other methods may be justified and may be
included as supporting information to establish the
effective dose.
3. Establishing starting dose
The decision on the first dose should be based on
a combination of the rationale for use in humans,
the biological effects observed in comparative ani-
mal studies, and the results of toxicity studies.
Specifically, the dose required to elicit the intended
biological effect must be within the recommended
dose based on the results of toxicity studies. Fur-
thermore, the dose must take into account the
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infectious titer of the viral preparation, as well as
the viral particle concentration. Both measures
must be within specification in order to achieve the
expected dose. It should be noted that detection of
adventitious agents, endotoxin and mycoplasma,
should also be within specification for the clinical
dosing plan.
Establishing dose may be complicated by the
proposed clinical plan. If theGTMP is planned to be
delivered as a single dose, clear justification for the
dose should be provided based on preclinical test-
ing, and the trial should be suitably powered to
handle this.
Should the selected starting dose be insufficient,
then the therapy will either fail or require further
intervention to provide an additional dose, and this
action must be clinically and ethically justified.
Conversely, too large a dose may result in adverse
events. If a large number of cells are required to
demonstrate expression in order to achieve the
desired clinical effect, this requirement will influ-
ence on the number of viral particles required,
with implications for risk of toxicity and adverse
side effects.
It should be noted that toxicity or adverse ef-
fects manifesting after longer periods of time post
treatment may not be recognized in preclinical
animal studies and may be missed in early-phase
trials. As a result, current guidance suggests
long-term follow-up of patients treated with gene
therapies.28
4. Bio-distribution of the GTMP
All organs listed in the EMA ‘‘Note for Guidance
on Repeated Dose Toxicity’’ should be checked for
bio-distribution of the gene or vector.29 Data must
be provided for all organs to address fully the risk of
off-target effects, germline integration, and viral
shedding. Generally, data obtained from the viral
vector are sufficient, without regard to the specific
promoter and transgene sequence.
With any medicinal product, the therapy must
provide its mode of action in the tissue where it is
required. The ability to do this will often depend
upon the method of introduction into the body.
Lentivirus has been demonstrated to remain
within a contained area and not to spread around
the body, thus providing high selectivity for target
tissue.30 Pseudo-typed with VSV-G or other enve-
lope protein demonstrating broad tropism, the virus
is likely to infect any cell within the target tissue.
With the inclusion of a cell-type specific promoter
within the lentivector transfer plasmid sequence,
the genetic material can be engineered to express
only in specific target cell types within the tissue.
As well as showing specific expression within a
tissue as required for the particular clinical indi-
cation, preclinical testing of GTMPs should also
address the duration of expression and activity
within the target tissues, especially when the
GTMP is designed to have selective or restricted
targeting and expression, such as the case with
inducible promoters.
The design of the third-generation lentivirus
means that infection and gene expression is likely
to remain located within the required targeted
area. Regulations also require investigation of the
mobilization, if any, of the GTMP throughout the
body, as well as risk of viral replication and of viral
shedding outside of the body (addressed in more
detail below). A key factor in bio-distribution is the
method of dosing, and so dosing quantities and
routes of delivery used in preclinical studies should
mimic the proposed clinical route.
5. Toxicity
To investigate toxicity, preclinical studies
should be carried out as closely to the proposed
clinical protocol as possible. They should utilize the
same route and method of administration, with
dosing mimicking clinical use with appropriate
safetymargins. In the case of gene therapies, study
guidance is in line with normal pharmaceuticals
provided by ICHM3.25 Toxicity should be assessed
for the whole GTMP, including the transgene
product, any vector-related non-therapeutic gene
products, and any impurities present in the viral
preparation. For this reason, it is best to run tox-
icity experiments on trial batches of viral vector
identical to the intended clinical-grade product,
produced by the sameGMPmanufacturing facility,
and using the same GMPmanufacturing platform.
Toxicity studies should be utilized to estab-
lish safety data and to explore suitable biomark-
ers predictive of toxicity for monitoring within
the clinical trial. Appropriate endpoints should be
specified, and may include necropsy, histopathol-
ogy, and nucleic acid testing such as qPCR to detect
specific sequences contained within the GTMP.26
The toxic potential is influenced by a number
of factors, including the number of vector parti-
cles, structural components of the vector and the
expression, and integration of the selected gene.
While studies should be based around the intended
transgene, the GTMP purity should be taken into
consideration with the toxicological consequences
of any aberrant gene product evaluated. Toxicity
testing should further take into account the risk of
insertional oncogenesis, expression levels of the
target gene and any other transgenes included in
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the therapy, and intracellular localization of the
gene product(s). The effect of any vector-related non-
therapeutic proteins will therefore also be required.
Due to the nature of GTMPs, with regard to re-
productive toxicology, the standard battery of tests
is generally not required (unless otherwise high-
lighted by the features of the proposed GTMP; e.g.,
if the gene therapy is specifically targeted toward
the reproductive organs). Since the vector has not
been detected in gonadal tissue following bio-
distribution studies, further germline integration
studies may not be warranted for individual new
lentiviral-based GTMPs.27 Any studies required
(e.g., for other types of viral vector) should be car-
ried out as per EMEA/273974/2005.31
As with pharmacological testing, toxicity testing
must be conducted in appropriate in vitro and
in vivo model systems. The animal model used for
such studies should be the most relevant and eth-
ically justified species to examine possible toxico-
logical effects. Design of experiments benefit from
use of the 3Rs—reduction, replacement, and re-
finement—as set out by Workman et al.,32 with
reporting adhering to ARRIVE guidelines for doc-
umentation of in vivo experiments, as set out by
Kilkenny et al.33 In particular, numbers of animals
used should be justified with a power calculation,
and alternative testing methods (e.g., in silico
modeling) can be used to enhance the justification
for reduction of animals used. The age and sex
of animals used must also be justified. Duration
of studies should be in line with ICHM3.25 For
single-dose administration and extended expres-
sion (e.g., longer than indicated by ICHM3),25
the duration of observation should at least re-
flect the duration of the expression. While guide-
lines propose that the duration of observation
should at least reflect the duration of the trans-
gene expression, it is understood that such stan-
dards cannot be met when expression is intended
to be lifelong.
In cases where an interaction with concomi-
tant medication can be foreseen in the clinical
setting, appropriate preclinical studies should be
undertaken.
6. Risks of toxicity due to route of delivery
An important issue that will vary amongst
GTMPs is the use of concomitant medication in
planned clinical trials and the potential for any
interaction between the two. Concomitant medi-
cationmay help support infection and integration of
the vector but may also reduce effectiveness. It
is therefore important to investigate any potential
impact.
7. Stability of the GTMP during the time
course of treatment
Data on the stability of the lentiviral vectors at
various temperatures should be provided, as these
provide a critical factor that may impact thera-
peutic efficacy in clinical settings. A significant
decrease in infectious titer was observed in lenti-
viral particles pseudo-typed with VSV-G when
stored at 4C instead of -80C, with an approxi-
mately 50% reduction in functional titer every
3 days.34 It is currently recommended that lenti-
viral vectors should be stored at -80C until ready
for use, and thawing should occur in a controlled
manner where possible.
8. Immunogenicity
Following on from the possible risk of toxicity
caused by the transgene and vector, the potential
impact on the host immune system must be in-
vestigated. This is especially important if the
encoded protein is known to affect the immune
system, if the encoded protein is not normally
present in that species, or if the expressed protein
has an altered structure in comparison to its nat-
ural counterpart. These issues could cause auto-
immune consequences. With regard to the vector,
third-generation lentivirus itself has been demon-
strated to have low immunotoxicity, but the effect
of the transgene itself will require its own justifi-
cation.35 White blood cell counts, T-cell activation,
hemadsorption, and other tests may be useful in
demonstrating humoral and/or cell-mediated im-
munity with a specific gene therapies product.
If repeated administration to patients is planned,
the impact of an immune response on the re-
administered GTMP should be investigated, as
patients may build immunity upon further expo-
sure. Animal models used for these studies should
be appropriate. These tests may need to be done
separately from efficacy studies if immunocompro-
mised animals are required for disease modeling.
9. Indexes for monitoring patients in gene
therapy clinical trials
Through the preclinical testing phase, markers
for monitoring within the clinical trial should be
identified. These should relate to the vector and
transgene product to monitor patient safety and
GTMP efficacy accurately with minimal testing.
The standard tests for detection of viral vector and
the production of replication-competent viruses are
nucleic acid testing such as qPCR, detection of a
viral antigen in blood, or marker-rescue assay, as
detailed in the European Pharmacopoeia.36 Ex-
pression of the genetic insert product should be
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determined using suitable immunochemical or
biochemical assays or by flow cytometry.
10. Establishing patient eligibility criteria
The eligibility criteria for patients within a
proposed clinical trial should take into consider-
ation the results of the preclinical testing. Any
potential risks identified from the tests should re-
sult in the removal of those patients at a greater
susceptibility. This is particularly necessary with
regard to first-in-human trials. As knowledge of the
GTMP is gained through the clinical trial phases,
the eligibility can be adjusted to take into account
the adjusted risks.
11. Level and persistence of gene expression
Preclinical studies on expression level after
viral-mediated gene therapy should include time
points for which there is no signal detection and
continue observation to cover persistence of the
duration of transgene expression and activity for
the period of time of the treatment. Because lenti-
viruses stably integrate into the host-cell genome
to allow expression of the transgene for the lifetime
of the cell, the persistence of this therapy may not
be able to be tested in preclinical models, but time
courses should be chosen to determine the biologi-
cal effects and toxicity of the promoter and trans-
gene sequences delivered by the GTMP.
Lentivirus does not have the capacity for la-
tency. If the parental virus has the capacity for
latency, it must be investigated if there is reason to
suspect this feature may persist in the modified
vector. If either is the case, tests must be conducted
to assess whether latency is restricted to specific
tissues and whether the vector has capacity for
reactivation. The strategy to address this issue
should be justified, with attention to concerns re-
garding tissue specificity and species specificity.
12. Localization and trafficking of the gene
therapy product
Localization and trafficking of the gene ther-
apy product may be altered by specific sequences
within the transgene, for example to facilitate
translocation to the plasma membrane or subcel-
lular compartments. While these sequences can
enhance function by ensuring that expressed gene
products are in the correct location to achieve their
intended role, these sequences can also change the
rate of protein degradation and recycling.37 So such
sequences must themselves be subject to testing
as part of the pharmacodynamics and efficacy of
the GTMP.
13. Risk of carcinogenesis, insertional
mutagenesis, and oncogenic transformation
Standard lifetime rodent carcinogenicity studies
required for most new IMPs are not generally re-
quired for GTMPs. The decision over whether the
tumorigenic or oncogenic potential needs to be
investigated should be guided by the Weight of
Evidence approach according to ICHS6 Carcino-
genicity.38 Tumorigenic and oncogenic potential
would only require further investigation should the
weight of evidence suggest a risk.
Integration studies may be required depending
on the proposed clinical use (e.g., if the target cell is
a proliferating cell type such as a stem cell). The
likelihood and possible consequences of vector in-
tegration should be evaluated, and measures to
control potential risks should be described and
justified.
Integration studies should focus on the tis-
sue where integration takes place, copy number
and localization of the integrated vector copies,
stability/persistency of the integrated vector cop-
ies, and number of potentially pathogenic integra-
tion events.39
Integration capacity can be determined by
demonstrating the incorporation of vector proviral
DNA into target cells using whole-genome se-
quencing. It is not clear at this time how regulatory
bodies will address this risk, given evidence that
lentivectors appear to insert randomly.40 The total
number of viral copies integrated can be evaluated
using limiting dilution techniques of transduced
cells and nucleic acid quantification assays such as
qPCR with probes targeted either to the transgene
or packaging signal.41 A significant advantage of
lentivirus is that it inserts genetic material into
the host genome, allowing continuous expression
in target cells. However, this feature theoreti-
cally increases tumor risk through insertional
mutagenesis. Studies have shown that lentiviral-
mediated gene delivery does not cause insertional
mutagenesis in oncogenic hotspots, thereby re-
ducing the theoretical risk of cellular transforma-
tion compared to other viral vectors.40 However,
random insertional mutagenesis still presents a
risk, as oncogenes and tumor suppressors are
present throughout the genome. Currently, inte-
gration for new lentiviral vector constructs is
studied by RNA sequencing in order to ensure that
integration of genetic material is indeed random,
independent of the promoter and transgene se-
quence. However, as the weight of evidence grows
for third-generation lentiviral vectors as modes of
gene therapy, the information available for this
vector may negate the need for full sequencing of
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the target cell genome with each new product.
Regulatory guidance advises that the oncogenic
potential of GTMPs can be tested in silico with
standard rodent carcinogenicity studies not being
required.26 However, the nature of the promoter and
transgene in themselves will possibly require sepa-
rate justification and/or targeted investigation.
14. Risk of germline transmission
Of particular importance within this area of
study is the risk of germline transmission. Direc-
tive 2001/20/EC states that no gene therapy trials
may be carried out that result inmodification to the
patient’s germline genetic identity.42 It is therefore
important to demonstrate the removal or avoid-
ance of this risk.
15. Risk of viral shedding
Environmental risk is based on the probability of
transmission of theGTMP from the patient to other
people, animals, plants, or the wider environment.
This risk is caused by viral shedding, the dissemi-
nation of the virus through secretions or excre-
tions. Viral shedding studies in an animal model
are normally recommended. However, lentivirus-
based gene therapy is demonstrably low risk in
this regard.43 Therefore, an environmental risk
assessment for this type of GTMP should not
necessitate the analysis of urine and feces post
administration.44
There are separate regulations regarding the
contained use and deliberate release of geneti-
cally modified microorganisms. Bio-distribution
and viral-shedding studies provide details for
the required environmental risk assessment, from
which clarification of the necessary regulation to be
followed is taken.45 Due to the specific nature of the
lentivirus, the use of third-generation lentivirus
should fall under the contained-use regulations.
16. Risk of replication competence
A key factor in the success of third-generation
lentivirus-mediated gene therapy is the ability
to transfer DNA without the risks associated with
the parental strain. The third-generation self-
inactivating vector system has been extensively
modified to eliminate virulent genes, includ-
ing those for viral replication.1–3 Yet, theoreti-
cally, recombination events may restore replication
competency after undergoing complementation
with wild-type viruses. Importantly, this has never
been observed with third-generation lentiviral
systems. The rationale for the engineered modifi-
cations underpinning the third-generation lenti-
virus to eliminate the possibility of virulence and
replication competency provide reassurances to-
ward these safety queries.
17. Sterility of viral preparation
Since ATMPs are biological materials that can
be easily destroyed through sterilization proce-
dures, the manufacturing of these products must
be conducted in such a way as to ensure aseptic
manufacturing. For non-sterile raw or starting
materials, additional steps may need to be taken to
ensure subsequent aseptic manufacturing (e.g.,
heat inactivation or sterile filtration of raw mate-
rials). The premises, equipment, raw materials,
and cell lines used must be in suitable conditions
for GMP manufacturing. At every stage of proces-
sing, materials and final products should be pro-
tected from microbial and other contamination.
Closed-systems manufacturing should be used
wherever possible.
18. Integrity of the genetic material
Two types of assessment may need to be con-
ducted to validate the integrity of the viral vector
and its components. First, the lentivector transfer
plasmid should be sequenced, and the genes in-
cluded should be justified. Co-transfected plas-
mids containing genes that encode packaging and
structural elements of the viral vector should be
sequenced as well. If a stably transduced cell line is
used to aid vector packaging, this cell line should be
well characterized. The sequences of the genes
used for vector packaging and the method used to
establish the stable cell line should be justified.
Second, the viral product can be subjected to
Southern blot analysis to ensure that recombination
of the sequence has not occurred during packaging.
ENGAGEMENT WITH KEY STAKEHOLDERS
TO ACHIEVE CLINICAL TRIAL
AUTHORIZATION
A number of key stakeholders must be ap-
proached in order to build a case for clinical trials
authorization, prior to submission of the applica-
tion to the national regulatory authority. These
parties are detailed in Table 3.
If possible, scientific advice should be sought
from the relevant regulatory authority to ensure
that development plans are acceptable and in line
with regulatory expectations. A note of caution
should be provided at this point, as authorities will
often only provide feedback on submitted proposals
and do not provide advice on product development.
As well as approval from regulatory bodies, any
proposed clinical trials must be reviewed by inde-
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pendent ethics committees to ensure the ethical
well-being of patients. The Declaration of Helsinki,
developed by the World Medical Association, en-
sures that the health and rights of individual pa-
tients takes precedence over any preconceived
wider good.46 Ethics committees, composed of ex-
perts and lay members, ensure that any per-
son proposing to take part in medical research is
provided with all of the information required
to make an informed decision to take part. This
is particularly important within first-in-human
studies when efficacy within humans is yet to be
demonstrated.
In the United Kingdom, there are specialist
ethics committees providing expertise in certain
types of clinical trials such as pediatrics, medical
devices, and gene therapy. Ethics committees, with
their makeup of volunteers, are often open to com-
menting on clinical trial proposals, which should
be actively sought. The use of specialized ethics
committees, while ensuring patient well-being, will
also help to ensure a smoother review process.
An important influence in ethical reviews is
whether patient groups or volunteers have been
involved in the production of patient documents
and protocol design. Establishing a patient advi-
sory group (PAG) ensures that the needs and the
acceptability to the patient are included within the
clinical plan. Using a PAG can provide valuable
knowledge on the information needing to be pro-
vided, the type of language that is acceptable and
understandable to lay persons, as well as the type
of procedures that people may be willing to un-
dergo. It must be remembered that ultimately if a
trial or therapy is not acceptable to patients, then it
will not progress anywhere. The inclusion of evi-
dence of support will provide a strong argument
for ethics committees that the trial is ethically ac-
ceptable for participants.
One of the primary stakeholders is the manu-
facturing partner or contract manufacturing or-
ganization (CMO). A manufacturing partner may
be a licensed facility for GMP production of ATMPs
within a university or hospital setting, while a
CMOmay be a licensed external facility that makes
the product to specification upon tech transfer.
Either way, the manufacturer should be a close
partner during the trial. In addition, an experi-
enced consultant acting as a third party may be
of benefit to ensure that all necessary steps are
taken to complete the application for clinical trial
authorization.
There will be a qualified person (QP) to examine
the quality control and quality assurance proce-
dures at the GMP manufacturing facility. The QP
will sign for batch release after specifications are
met. The pharmacy at the location of the clinical
trial will also need to be involved in the trial, and
relevant personnel must be suitably trained in the
storage, transfer, dilution, and use of ATMPs.
Sponsors of a clinical investigation take respon-
sibility for the initiation of the trial, management,
and financing. The sponsor is a vital component of
a clinical trial, with specific legal responsibilities
regarding obtaining and maintaining regulatory
authorizations, how the trial is conducted, phar-
macovigilance, and the IMP. The sponsor is
accountable for ensuring the authorization re-
quirements for manufacturing are met, that certi-
fication of an IMP is done by a QP, and that the
final product undergoes a two-step release process
and is labeled correctly according to the regula-
Table 3. Stakeholders to involve in the process of gene
therapies clinical translation
Identify a CMO with a licensed facility for manufacturing ATMPs under GMP,
with demonstrated capabilities
 Ensure that the CMO has a manufacturing license from the relevant national
regulatory body.
 Ensure that master cell bank is expanded to be licensed for GMP manufacture
as a viral producer cell line.
 Ensure that lentivector transfer plasmid and packaging plasmids are amplified
to a sufficiently high quality and are licensed for clinical use.
 Ensure that all non-biological raw materials are traceable from origin and
certified for GMP use.
 Ensure that raw materials of animal or human origin (e.g., fetal bovine serum)
are sourced, treated, and certified appropriately. Avoid their use if possible.
 Query QC processes that will ensure manufacturing and batch testing will be
conducted to specification and documented appropriately.
 Query QA audit documentation procedures that will be in place to ensure that
QC manufacture and batch testing will be compatible with relevant regulatory
standards.
 Identify a QP (a specials-licensed pharmacist) to plan for product labeling and
batch release.
Seek local trial sponsorship through a research hospital capable of running
a clinical trial
 Ensure research governance is in place.
 Ensure the sponsor of the trial has clear expectations for IB and IMPD
documentation.
 Ensure the pharmacy specials team and QP are involved on-site.
 Ensure the local GM committee and clinical virologists are involved in the
clinical trial.
 Ensure there are clear plans for data collection, storage, and transfer
between institutions as needed.
Bridge with clinicians who will be administering the ATMP
 Ensure training, equipment, and strong communication across the team is in
place to address specific challenges regarding the administration of the gene
therapy to patients.
 Ensure there are clear plans for pharmacovigilance during the clinical trial.
Seek advice from ethics committees on GTMPs. Advisory committees may be in
place locally, with the trial sponsor, and nationally
Seek advice from patients and patient advocates by gathering an advisory
group. Engage in public outreach to build support for the project.
CMO, contract manufacturing organization; QC, quality control; QA,
quality assurance; QP, qualified person; IB, investigational brochure; IMPD,
investigational medicinal product dossier.
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tions. While individuals are capable of taking on
the role of sponsor, this is very rarely seen due to
the risks and legal liabilities involved. Within
noncommercial studies, the role is often taken on
by the substantive employee of the chief investi-
gator or the lead healthcare organization within
the trial. Sponsorship responsibilities within the
United Kingdom can be shared between two
organizations. This is called co-sponsorship. Co-
sponsorship is not recognized within other EU
states, and local arrangements should be checked
before embarking on co-sponsorship. Discussions
regarding sponsorship should be held early in or-
der to ensure that all responsibilities can be ade-
quately performed. Trials involving ATMPs have
additional regulatory and reporting requirements
compared to standard IMPs. Sponsors must be
aware of these and have suitable resources and
facilities in place to ensure compliance. Sponsors
will also take on a degree of legal liability andmust
ensure adequate insurance is in place.
When applying for funding, funders may ask as
part of their application for assurances that there
is a sponsor lined up. This will help provide guar-
antees that their money will not go to waste. Fun-
ders for investigator-led trials are very unlikely to
be able to act as sponsor, and it is rarely in their
interest to take on the required responsibilities.
This is the case for funding provided to indepen-
dent investigators by commercial and noncom-
mercial funders.
There are a number of other considerations that
need to be taken into account when planning a
clinical trial. These include how data collected
within a study will be used and stored, and how
this complies with data-protection laws. This is
particularly important if data are being trans-
ferred across borders and continents where the
laws governing the use of personal data may vary.
Similarly, the laws and regulations surrounding
the collection and use of human tissue should be
investigated alongside any planned exposure to
radiation or radioactivematerial as part of the trial
protocol. A general principle when planning trials
is to ensure that all procedures and assessments
are justifiable, that it is all clearly detailed and
explained within patient information sheets, and
that consent is taken. As part of gathering all the
necessary approvals to begin a clinical trial, it must
be assured that reviews will take place to ensure
compliance with all necessary laws and regulations
and that necessary governance procedures are in
place for the duration of the trial.
Taking a gene therapy product from conception
to marketing is a long, complicated, expensive, and
risky business, with no guarantees that treat-
ments will be efficacious and safe enough to be ta-
ken up by themedical community. Gaining support
from corporate partners and clinicians through
the development process is important, as they can
provide valuable guidance, expertise, and contacts.
As a product develops and undergoes continuous
testing, information on the product accumulates,
and the risk profile decreases. Outsourcing par-
ticular steps of gene therapies manufacture (e.g.,
GMP or high-quality plasmid amplification, GMP
virus manufacture, good laboratory practice [GLP]
toxicity testing) through CMOs can increase the
speed and reliability of process development. Re-
quirements from regulators for GMP manufac-
ture and GLP testing of medicinal products are
very specific and cannot simply be set up for one-
off products.
MINIMUM DOCUMENTATION REQUIRED TO
ACHIEVE CLINICAL TRIAL AUTHORIZATION
Applications for regulatory approval include a
number of standard documents. While most of the
documents cannot be completed until all preclinical
testing is completed, there is nothing to stop in-
vestigators from beginning work early. This will
also help to identify areas requiring further work
as the project develops. The investigational bro-
chure (IB) and investigational medicinal product
dossier (IMPD) will together provide details re-
garding the GTMP and contain a degree of over-
lap. The IB provides a summary for investigators of
the clinical and preclinical data relevant to the
proposed clinical trial. The IMPD is a more in-
depth document providing detailed information on
the gene therapy product, including structure,
manufacturing procedures, quality control consid-
erations, and preclinical and clinical data sets. The
minimum documents required for submission of a
clinical trials authorization is given in Table 4.
Table 4. Minimum documentation required for submitting
an application for clinical trial authorization
to a national regulatory authority
 Clinical trial application form
 Protocol
 IB
 IMPD
 Summary of scientific advice from the EMA or FDA, if obtained
 CMO manufacturing authorization
 Labeling of IMP content and expiry date
 Patient documents, including information sheet and consent form
 Summary curriculum vitæ of chief investigator
 Evidence of insurance
 Evidence of independent peer review
EMA, European Medicines Agency; FDA, Food and Drug Administration.
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It takes a large team and a high degree of over-
sight to develop aGTMP. The guidance provided by
regulatory authorities, such as the risk-based ap-
proach in respect to quality, safety, and efficacy,
provide useful information for planning product
development. Similarly, effective communication
with each of the stakeholders is important to re-
duce the risk of substantial delays. Documentation
can aid this process greatly.
The use of GTMPs and the use of lentiviral vec-
tors in particular is still relatively new for inves-
tigators and regulatory authorities. As more
information on these products is released, regula-
tions and guidance will likely increase. It is there-
fore important to make regular checks to ensure
trial planning is based on the most up-to-date in-
formation.
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